Waiv, formerly Owkin Dx

📍 Paris, France🗓 Founded 2026👥 46 employees💰 Last funded Mar 2026
Biotechnology Research🌐 wearewaiv.com
Website LinkedIn
Waiv has evolved to meet this moment: Hundreds of novel innovations are entering clinical development each year, while biomarker testing complexity and costs are surging. As healthcare undergoes a broader shift toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics. Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind. Waiv, a spin-out of Owkin (https://www.owkin.com/), capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC (https://www.owkin.com/diagnostics/rlapsrisk-bc), to unlock morphological insights and future-proof the clinical diagnostic workflow.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2026
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Luxembourg
1
France
1
Frequently asked questions
Who invested in Waiv, formerly Owkin Dx?
Waiv, formerly Owkin Dx has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Waiv, formerly Owkin Dx last raise funding?
The most recent investment in Waiv, formerly Owkin Dx recorded on gritt.io was in March 2026.
When was Waiv, formerly Owkin Dx founded?
Waiv, formerly Owkin Dx was founded in 2026.
What industry is Waiv, formerly Owkin Dx in?
Waiv, formerly Owkin Dx operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Waiv, formerly Owkin Dx based?
Waiv, formerly Owkin Dx is headquartered in Paris, France.